Knowing the Difference is Critical

Ambry Genetics®
A Konica Minolta Company

Rule out or confirm a diagnosis of Lynch syndrome with one efficient test.

TUMORNEXT-*LYNCH*
Identifies both germline and somatic mutations in the Lynch syndrome genes

GERMLINE (HEREDITARY)

IDENTIFY PATIENTS WITH LYNCH SYNDROME

- One germline mutation indicates a diagnosis of Lynch syndrome; manage based on NCCN® guidelines[2]

TUMOR (SOMATIC)

EXPLAINS UP TO 70% OF DISCORDANT TUMOR VS. GERMLINE RESULTS

- Two somatic mutations = Reduced likelihood of Lynch syndrome; manage based on family history[1,2]
- One somatic mutation may indicate undetectable Lynch syndrome; manage based on NCCN® guidelines[2]

WHY ORDER TUMORNEXT-*LYNCH*?

GET MORE COMPLETE INFORMATION TO GUIDE HEALTHCARE DECISIONS WITH ONE TEST

- Rule out or confirm a diagnosis of Lynch syndrome
- Clarify cancer risks so you can modify screening and prevention recommendations
- Guide treatment based on mismatch repair deficiency and/or *BRAF/KRAS/NRAS* mutation status

Ambry Genetics®
A Konica Minolta Company

Who Should Have TumorNext-*Lynch*?

Patients with colorectal or endometrial cancer and any of the following:

- Abnormal MSI/IHC and no previous Lynch syndrome germline testing
- Abnormal MSI/IHC and previously negative germline Lynch syndrome genetic testing
- A personal and/or family history suggestive of Lynch syndrome

One test looks at both tumor and germline to bring more clarity for your patients.

TEST DETAILS

TUMORNEXT-*LYNCH** INCLUDES:

- Paired tumor/germline analysis of *MLH1, MSH2, MSH6, PMS2,* and *EPCAM*
- *MLH1* promoter hypermethylation analysis
- Microsatellite instability (MSI) analysis
- Option to add on *BRAF* (V600E) and targeted *NRAS* and *KRAS* analysis

** Test options available to add ColoNext, OvaNext, or CancerNext germline testing to TumorNext-Lynch*

Turnaround Time

21-28 days (once both samples are received)

Acceptable Specimen Types

Lynch syndrome tumors accepted^ for testing. Visit ambrygen.com/tumornext-lynch for complete details.

^ Pathology report also required with order

ORDERING PROCESS

1. Complete Tumor Test Requisition Form (TRF) and submit with blood sample and relevant pathology report (required)
2. Ambry will contact the pathology department to request the tumor specimen
3. Testing will begin when the blood and tumor samples are both received; both are required for processing

Please note that the time to receive the tumor specimen depends on individual pathology departments and may delay testing. Follow-up may be needed.

References

1. Haraldsdottir S, et al., Gastroenterology. 2014 December;147(6):1308-16.
2. NCCN Clinical Practice Guidelines in Oncology®. Genetic/Familial High-Risk Assessment: Colorectal. V.1.2017

15 Argonaut, Aliso Viejo, CA 92656 USA Toll Free +1 866 262 7943 Fax +1 949 900 5501 ambrygen.com